Compare OLOX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLOX | VRAX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 972.3K |
| IPO Year | 2011 | 2021 |
| Metric | OLOX | VRAX |
|---|---|---|
| Price | $0.57 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 551.0K |
| Earning Date | 12-01-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,952,578.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.10 |
| 52 Week High | $219.00 | $13.19 |
| Indicator | OLOX | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 16.96 |
| Support Level | $0.45 | $0.15 |
| Resistance Level | $1.29 | $0.53 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 15.99 | 5.26 |
Olenox Industries Inc provides modular structures made from code-engineered cargo shipping containers as permanent or temporary structures for residential housing, commercial structures, and industrial applications. Its segments are: Construction, Software-as-a-Service (SaaS), Oil and Gas, and Others. Construction segment generates maximum revenue and designs and constructs modular structures in its factory using recycled shipping containers; in the past, traditional wood and steel frames were also used. It markets its construction products to contractors, home builders, building owners, other resellers, large multinational corporations, government agencies, private developers, the U.S. Military, individual homeowners, and pop-up retailers across the continental United States and Canada.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.